After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
At least 15 dual-payload ADCs will be discussed.
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
Ikena, Senti and others look to clinical presentations at AACR.
